TARDBP Mutations in Amyotrophic Lateral Sclerosis

TARDBP Mutations in Amyotrophic Lateral Sclerosis

Overview

Tardbp Mutations In Amyotrophic Lateral Sclerosis plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.

Introduction

Mutations in the TARDBP gene, which encodes the [TDP-43](/mechanisms/tdp-43-proteinopathy) protein, are a well-established cause of familial amyotrophic lateral sclerosis (ALS)[@disruption][@amyotrophic]. TDP-43 is the major pathological protein in virtually all ALS cases (except those caused by SOD1 or FUS mutations), making understanding TARDBP mutations crucial for comprehending ALS pathogenesis.

Genetics

Gene Overview

The TARDBP gene is located on chromosome 1p36.22 and encodes:

• Protein: TAR DNA-binding protein 43 (TDP-43)
• Function: RNA-binding protein involved in RNA splicing, stability, and transport
• Molecular weight: ~414 amino acids
• Key domains: N-terminal domain, RNA recognition motif (RRM), C-terminal glycine-rich domain

Pathogenic Mutations

Over 50 pathogenic TARDBP mutations have been identified:

| Mutation | Location | Frequency | Phenotype |
|----------|-----------|-----------|-----------|
| A382T | C-terminal | Most common | Classic ALS |
| M337V | C-terminal | Common | ALS/FTD |
| G298S | C-terminal | Rare | Early onset |
| Q331K | C-terminal | Rare | Variable |
| N345K | C-terminal | Rare | ALS |
| D169G | RRM | Rare | FTD |

...

TARDBP Mutations in Amyotrophic Lateral Sclerosis

Overview

Tardbp Mutations In Amyotrophic Lateral Sclerosis plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.

Introduction

Mutations in the TARDBP gene, which encodes the [TDP-43](/mechanisms/tdp-43-proteinopathy) protein, are a well-established cause of familial amyotrophic lateral sclerosis (ALS)[@disruption][@amyotrophic]. TDP-43 is the major pathological protein in virtually all ALS cases (except those caused by SOD1 or FUS mutations), making understanding TARDBP mutations crucial for comprehending ALS pathogenesis.

Genetics

Gene Overview

The TARDBP gene is located on chromosome 1p36.22 and encodes:

• Protein: TAR DNA-binding protein 43 (TDP-43)
• Function: RNA-binding protein involved in RNA splicing, stability, and transport
• Molecular weight: ~414 amino acids
• Key domains: N-terminal domain, RNA recognition motif (RRM), C-terminal glycine-rich domain

Pathogenic Mutations

Over 50 pathogenic TARDBP mutations have been identified:

| Mutation | Location | Frequency | Phenotype |
|----------|-----------|-----------|-----------|
| A382T | C-terminal | Most common | Classic ALS |
| M337V | C-terminal | Common | ALS/FTD |
| G298S | C-terminal | Rare | Early onset |
| Q331K | C-terminal | Rare | Variable |
| N345K | C-terminal | Rare | ALS |
| D169G | RRM | Rare | FTD |

Mutation Distribution

• Majority: Located in C-terminal glycine-rich region
• Effect: Protein mislocalization and aggregation
• Inheritance: Autosomal dominant

Molecular Mechanisms

Normal TDP-43 Function

TDP-43 is a nuclear RNA-binding protein that:

• Regulates alternative splicing
• Stabilizes mRNA transcripts
• Participates in RNA processing
• Modulates gene expression

Pathogenic Mechanisms

1. Protein Mislocalization

• Mutant TDP-43 accumulates in cytoplasm
• Loss of nuclear function
• Formation of stress granules
• Progression to inclusions[@tdp]

2. Aggregation

• C-terminal mutations promote aggregation
• Insoluble inclusions in [neurons](/entities/neurons)
• Sequestration of normal TDP-43
• Disruption of RNA metabolism

3. RNA Processing Defects

• Aberrant splicing patterns
• Altered mRNA stability
• Disrupted transport to synapses
• Impaired stress response

4. Loss of Function

• Reduced nuclear TDP-43 activity
• Dysregulation of critical neuronal transcripts
• Nuclear depletion in disease

TDP-43 Pathology in ALS

TDP-43 inclusions are the hallmark of ALS:

• Location: Motor neurons, surrounding glia
• Composition: Phosphorylated, ubiquitinated TDP-43
• Types: Skeletal, compact, Lewy body-like

Clinical Features

Typical Presentation

• Age of onset: 45-65 years (variable)
• Site of onset: Limb (70-80%) or bulbar (20-30%)
• Progression: Variable, typically 2-5 years
• Survival: Similar to sporadic ALS

Mutation-Specific Features

| Mutation | Onset | Progression | Notes |
|----------|-------|-------------|-------|
| A382T | ~50 years | Variable | Most common, Italy cluster |
| M337V | ~52 years | Variable | ALS/FTD possible |
| G298S | ~45 years | Variable | Early onset |

Clinical Characteristics

• Classic ALS phenotype: Mixed upper/lower motor neuron
• Cognitive involvement: 10-15% develop FTD
• Extrapyramidal features: Possible in some families
• Respiratory involvement: Common progression

Diagnosis

Genetic Testing

• Method: PCR and Sanger sequencing
• Indication: ALS with family history, early onset
• Interpretation: Pathogenic variants confirm genetic etiology

Biomarkers

| Biomarker | Relevance |
|-----------|-----------|
| Total TDP-43 in CSF | May be elevated |
| [Neurofilament light](/biomarkers/neurofilament-light-chain-nfl) chain (NfL) | Disease progression marker |
| Phosphorylated TDP-43 | Diagnostic in research |

Therapeutic Approaches

Current Strategies

1. Antisense Oligonucleotides (ASOs)

• ASOs targeting mutant TARDBP mRNA
• Challenge: Balancing mutant reduction with normal function
• Preclinical development ongoing

2. Aggregation Modulators

• Small molecules preventing aggregation
• Enhancement of protein clearance

3. RNA Processing Modulators

• Correcting splicing dysregulation
• Stabilizing mRNA transcripts

Research Directions

• Gene therapy: Viral delivery of ASOs
• Protein homeostasis: Enhancing [autophagy](/entities/autophagy)/ubiquitin system
• Neuroprotection: Addressing oxidative stress
• Cell-based therapies: Stem cell approaches

Animal Models

Transgenic Models

• TARDBP transgenic mice: Show TDP-43 pathology
• Mutant knock-in mice: Model human disease
• iPSC-derived neurons: Patient-specific models

Key Findings

• Mutant TARDBP sufficient for neurodegeneration
• TDP-43 pathology spreads in CNS
• Non-neuronal cells contribute
• Therapeutic window exists

TDP-43 Across ALS Subtypes

TDP-43 pathology is present in:

• SOD1-ALS: Rare, usually absent
• FUS-ALS: TDP-43 negative inclusions
• [C9orf72](/entities/c9orf72): TDP-43 positive
• Sporadic ALS: Universal TDP-43 pathology
• [Amyotrophic Lateral Sclerosis (ALS) Genetic Variants](/diseases/als-genetic-variants)
• [ALS-FTD Spectrum](/diseases/als-ftd-spectrum)
• [TARDBP Gene](/tardbp-gene)
• [TDP-43 Pathology in Neurodegeneration](/mechanisms/tdp-43-pathology)
• [Protein Aggregation Mechanisms](/mechanisms/protein-aggregation)

Overview

Tardbp Mutations In Amyotrophic Lateral Sclerosis plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.

Background

The study of Tardbp Mutations In Amyotrophic Lateral Sclerosis has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Recent Research (2024-2026)

This section highlights recent publications relevant to this disease.

• [Disruption of the angiopoietin-like system connects lipid homeostasis and hypothalamic dysfunction in ALS.](https://pubmed.ncbi.nlm.nih.gov/41776545/) (2026 Mar 3) - BMC medicine
• [Amyotrophic Lateral Sclerosis (ALS) Genetics and Microbiota: A Comprehensive Review.](https://pubmed.ncbi.nlm.nih.gov/41752118/) (2026 Feb 19) - International journal of molecular sciences
• [TDP-43 directly inhibits mRNA accumulation in neurites through modulation of mRNA stability.](https://pubmed.ncbi.nlm.nih.gov/41398473/) (2026 Feb) - The EMBO journal
• [Deciphering ALS-linked genetic variants in indian patients using targeted and exome sequencing approaches.](https://pubmed.ncbi.nlm.nih.gov/41137727/) (2026 Feb) - Amyotrophic lateral sclerosis & frontotemporal degeneration
• [Mutant TDP-43 drives impairments in axonal transport and glycolysis in a mouse stem-cell-derived motor neuron model of amyotrophic lateral sclerosis (ALS).](https://pubmed.ncbi.nlm.nih.gov/41620396/) (2026 Jan 31) - Cell death & disease

References

• Amyotrophic Lateral Sclerosis (ALS) Genetic Variants
• ALS-FTD Spectrum
• [TARDBP](/genes/tardbp)
• TDP-43 Pa- RNA-Binding Proteins in Neurodegeneration
• SOD1 Mutations in ALS

External Links

• [ALS Association](https://www.als.org)
• [Motor Neurone Disease Association](https://www.mndassociation.org)
• [NIH: Amyotrophic Lateral Sclerosis](https://www.ninds.nih.gov/disorders/amyotrophic-lateral-sclerosis-als)
• [PubMed: TARDBP ALS Research](https://pubmed.ncbi.nlm.nih.gov/?term=TARDBP+ALS)
• [TDP-43 Biology Resources](https://www.ncbi.nlm.nih.gov/pmc/?term=TDP-43+ALS)